



Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 5

Application Number	10/734,031
Filing Date	December 11, 2003
First Named Inventor	Zaczek
Group Art Unit	1616 / 618
Examiner Name	TBD
Attorney Docket Number	BMS-PH-7048-A(C)


US PATENT DOCUMENTS

Exam Init	Ref Des	Document No.	Issue Date	Name	Class	Sub Class	FILING DATE If Appropriate
78	1	5,506,242	04/09/1996	MacPherson et al.			
	2	5,538,845	07/23/1996	Knops et al.			
	3	5,552,419	09/03/1996	MacPherson et al.			
	4	5,593,846	01/14/1997	Schenk et al.			
	5	5,594,006	01/14/1997	Sakamoto et al.			
	6	5,672,598	09/30/1997	De et al.			
	7	5,734,054	03/31/1998	Dolle, III et al.			
	8	5,703,129	12/30/1997	Felsenstein et al			
	9	5,942,400	08/24/99	Anderson et al			
	10	5,766,846	06-1998	Schlossmacher et al			
	11	6,737,038	05/18/2004	Zaczek at al			
	12	6,331,408	12/18/2001	Zaczek et al			
	13	5,604,102	02-1997	McConnlogue et al.			
	14	5,744,346	04-1998	Chrysler et al			
	15	6,329,163	12-2001	Anderson et al.			
	16	5,843,941	12/1/98	Marsters et al			
	17	5,532,359	7/2/96	Marsters et al.			
	18	5,721,106	02/1998	Maggio et al.			

FOREIGN PATENT DOCUMENTS

		Country & Doc. No. (11)	Pub. Date (43)		Class	Sub Class	Translation Yes No	
20	19	WO-95/09838	04/13/1995	Cordell et al.				
	20	WO 96/29313	09/26/1996	Wahl et al.				
	21	WO 98/22493	05/28/1998	Thorsett et al.				
	22	WO-98/22494	05/28/1998	Audia et al.				
	23	WO 98/28268	07/02/1998	McDaniel et al.				
	24	WO-98/38177	03/09/1998	Thorsett et al				
	25	WO 99/66934	12/29/1999	Audia et al.				
	26	WO-99/67219	12/29/1999	Elan Pharmaceuticals Inc.				

[Handwritten signature] 1/6/06



Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 5

Application Number	10/734,031
Filing Date	December 11, 2003
First Named Inventor	Zaczek
Group Art Unit	1618 / 1618
Examiner Name	TBD - D Jones
Attorney Docket Number	BMS-PH-7048-A(C)

FOREIGN PATENT DOCUMENTS

Class Subcl

27	WO-99/67220	12/29/1999	Elan Pharmaceuticals Inc.				
28	WO 99/67221	12/29/1999	McDaniel et al.				
29	WO 00/24392	05/04/2000	Ito et al.				

OTHER ART

(including Author, Title, Date, Pertinent Pages, Publication, Etc.)

30	A. Ahmed et al., <i>FEBS Letters</i> , (1984), vol.174, pp. 76-79
31	Arora et al., <i>J. Med. Chem.</i> , 30: p.918 (1987)
32	P. Becket, M. J. Crimmin, M. H. Davis, and Z. Spavold, <i>Synlett</i> (1993), pp. 137-138
33	Bock et al., <i>J. Med. Chem.</i> 1993, 36, pp.4276-4292.
34	Bock et al., <i>J. Org. Chem</i> 1987, 52, pp. 3232-3239
35	F. A. Carey and R. J. Sundberg, "Advanced Organic Chemistry, Part A," <i>New York: Plenum Press</i> , 1990, pp. 304-305, 342-347, 475-479, 695-698
36	Chumpradit et al., <i>J. Med. Chem.</i> , 32: p. 1431 (1989)
37	Chumpradit et al., <i>J. Med. Chem.</i> , 34: p. 877 (1991)
38	Ellis et al., <i>Aust. J. Chem.</i> , 26,: p. 907 (1973)
39	Evans, A et al. <i>Org.Synth.</i> 68.p83-91 (1990)
40	Glennner and Wong, <i>Biochem. Biophys. Res. Commun.</i> 120; pp.885-890
41	Ghosh et al. <i>JACS</i> (2000) 122 pp.3522-3523
42	J. Higaki, D. Quon, Z. Zhong, B. Cordell, "Inhibition of beta-amyloid Formation identifies Proteolytic Precursors and Subcellular Site of Catabolism", <i>Neuron</i> 14, pp. 651-659, 1995
43	Jacobson and Reddy, <i>Tetrahedron Letters</i> , Vol 37, No. 46, pp.8263-8266
44	Kabalka et al., <i>J. Label. Compound. Radiopharm.</i> , 19: p. 795 (1982)
45	A. S. Kende et al., <i>Tetrahedron Lett.</i> 1989, 30 (43), 5821-5824
46	K. S. Kirshenbaum, K. B. Sharpless, <i>J. Org. Chem.</i> (1985), 50 (11), pp. 1979-1982

2 1/6/06

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 5

Application Number	10/734,031
Filing Date	December 11, 2003
First Named Inventor	Zaczek
Group Art Unit	1616 1618
Examiner Name	TBD [Signature]
Attorney Docket Number	BMS-PH-7048-A(C)

OTHER ART

(including Author, Title, Date, Pertinent Pages, Publication, Etc.)

47	P. Kocienski, <i>Tetrahedron</i> 1990, 46, pp. 1767-1782
48	Koch et al., <i>Chem. Ber.</i> , 124: p. 2091 (1991)
49	Levitan, D. and Greenwald, I. <i>Nature</i> , 377, pp 351-354, 1995
50	Lin et al., <i>PNAS</i> (2000) 97: pp. 1456-1460.
51	Mach et al., <i>J. Med. Chem.</i> , 1993, 36, pp. 3707-3720
52	McClure and Axt, <i>Bioorganic & Medicinal Chemistry Letters</i> , 8 (1998), pp. 143-146
53	Merkushev, <i>Synthesis</i> , 923 (1988)
54	C. F. Nutaitis and M. W. Ledebor, <i>Org. Prep. Proced. Int.</i> (1992), 24 (2), pp. 143-146
55	Pratt et al., <i>Synlett</i> , May 1998, p. 531
56	M. P. Reddy and P. J. Voelker, <i>Int. J. Pept. Protein Res.</i> 1998, 31, pp.345-348
57	"Remington's Pharmaceutical Sciences," 17 th ed. Mack Publishing Company, Easton, PA, 1985, p.1418.
58	D. J. Selkoe, "Cell Biology of the amyloid (beta)-protein precursor and the mechanism of Alzheimer's disease," <i>Annu. Rev. Cell. Biol.</i> , 1994, 10: pp 373-403
59	Seevers et al., <i>Chem. Rev.</i> , 82, p. 575 (1982)
60	Sherrill and Sugg, <i>J. Org. Chem.</i> 1995, 60, pp. 730-734
61	Vassar et al., <i>Science</i> 1999 286: pp. 735-741
62	D. A. Walsh, <i>Synthesis</i> , September 1980, p.677
63	Wilbur et al., <i>J. Label. Compound. Radiopharm.</i> , 1982 19: p. 1171
64	Eckart et al, <i>J. Org. Chem.</i> , 1986 51: p. 483- 486
65	Wolf, Chrisman, Fowler, Lambrect, "Synthesis of Radiopharmaceuticals and Labeled Compounds Using Short-Lieved Isotopes," in <i>Radiopharmaceuticals and Labeled Compounds</i> , Vol. 1, 1973, pp. 345-381.

1/6/06

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

4

of

5

Application Number

10/734,031

Filing Date

December 11, 2003

First Named Inventor

Zaczek

Group Art Unit

1016

Examiner Name

IBD

Attorney Docket Number

BMS-PH-7048-A(C)

OTHER ART

(including Author, Title, Date, Pertinent Pages, Publication, Etc.)

	66	Book	M.Keen (ed) Receptor binding techniques methods in molecular Biology, Vol 106, Humana Press, Totowa, New Jersey, 1999
.	67		Eckelman et al. J.Nucl. Med, Vol. 20(4) pp.350-357 (1979)
.	68		T.W.Green and Wuts, Protective Groups in organic Synthesis (Wiley 1991)
.	69		Tubis and Wolf, eds Radiopharmacy, Wiley-Interscience New York (1976) Vol 1 p.345-381(1973)
.	70		Wilson et al. J.Org.Chem 51 4833 (1986)
↓	71		U.S. Pharmacopia-The National Formulary 22 nd Revision, Mack Printing Co. Easton, Pa 1990. "Radioactive Pharmaceuticals" relevant sections as per Index on page 2049
	72	Book	A. Macowski Medical Imaging Systems ed. Prentice-Hall, Inc Englewood Cliffs NJ(1983)
	73		E.I. Rogaev et al. Nature, Vol 376 pp 774-778 (1995)

1/4/06

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 5

Application Number	10/734,031
Filing Date	December 11, 2003
First Named Inventor	Zaczek
Group Art Unit	1616
Examiner Name	TBD
Attorney Docket Number	BMS-PH-7048-A(C)

FOREIGN PATENT DOCUMENTS

		Country & Doc. No. (11)	Pub. Date (43)		Class	Sub Class	Translation Yes No	
	74	WO 95/22966	08/31/1995	Mathiowetz et al.				
	75	EP0652009	05/10/1995	Dovey et al.				
	76	EP0276436	12/10/1987	Broadhurst et al.				
	77	EP0606046	12/21/1993	MacPherson et al.				
	78	WO 92/00374	01/09/1992	Nelson Et al.				
	79	WO 92/06966	04/30/1992	Markwell et al.				
	80	WO 98/15828	04/16/1998	Cordell et al.				
	81	WO-00/28331	05-2000	Zaczek et al.				

OTHER ART

(including Author, Title, Date, Pertinent Pages, Publication, Etc.)

82	M. G. Natchus et al., "Design and synthesis of conformationally constrained MMP inhibitors," Chemical Abstracts, vol. 129, no. 22, 30 November 1998, abstract no. 290051p.
----	--

Examiner Signature		Date Considered	1/16/06
-----------------------	--	--------------------	---------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ² Unique citation designation number. ³ See attached Kinds of U.S. Patent Documents. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231